Therapeutic activities of engrafted neural stem/precursor cells are not dormant in the chronically injured spinal cord

Stem Cells

Volumn 31, Issue 8, 2013, Pages 1535-1547

  Kumamaru, Hiromi ^a   Saiwai, Hirokazu ^a   Kubota, Kensuke ^a   Kobayakawa, Kazu ^a   Yokota, Kazuya ^a   Ohkawa, Yasuyuki ^a   Shiba, Keiichiro ^b   Iwamoto, Yukihide ^a   Okada, Seiji ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SPINAL INJURIES CENTER   (Japan)

Author keywords

Gene expression; Neural stem cell; Spinal cord injury; Stem cell transplantation

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; NEUROTROPHIN 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RANTES; SCATTER FACTOR; SOMATOMEDIN C; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN B;

ACUTE PHASE RESPONSE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENGRAFTMENT; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; INFLAMMATION; MACROPHAGE; MICROENVIRONMENT; MICROGLIA; MOLECULAR DYNAMICS; MONOCYTE; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEURAL STEM CELL TRANSPLANTATION; NEUTROPHIL; NONHUMAN; OLIGODENDROGLIA; REGENERATIVE ABILITY; RNA SEQUENCE; SPINAL CORD INJURY; TRANSCRIPTION INITIATION; TREATMENT RESPONSE;

GENE EXPRESSION; NEURAL STEM CELL; SPINAL CORD INJURY; STEM CELL TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CHRONIC DISEASE; FEMALE; MICE; MICE, INBRED C57BL; NEURAL STEM CELLS; NEUROGENESIS; SPINAL CORD; SPINAL CORD INJURIES;

EID: 84883399225     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1404     Document Type: Article

References (57)

1. Beattie MS. Inflammation and apoptosis: Linked therapeutic targets in spinal cord injury. Trends Mol Med 2004;10:580-583.
2. Thuret S, Moon LDF, Gage FH. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 2006;7:628-643.
3. Ruff CA, Wilcox JT, Fehlings MG. Cell-based transplantation strategies to promote plasticity following spinal cord injury. Exp Neurol 2012;235:78-90.
4. Barnabe-Heider F, Frisen J. Stem cells for spinal cord repair. Cell Stem Cell 2008;3:16-24.
5. Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders - Time for clinical translation? J Clin Investig 2010;120: 29-40.
6. Aboody K, Capela A, Niazi N et al. Translating stem cell studies to the clinic for CNS repair: current state of the art and the need for a rosetta stone. Neuron 2011;70:597-613.
7. Breunig JJ, Haydar TF, Rakic P. Neural stem cells: Historical perspective and future prospects. Neuron 2011;70:614-625.
8. Cummings BJ, Uchida N, Tamaki SJ et al. Human neural stem cells differentiate and promote locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci USA 2005;102:14069-14074.
9. Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci 2006;7:395-406.
10. Dobkin BH, Curt A, Guest J. Cellular transplants in China: Observational study from the largest human experiment in chronic spinal cord injury. Neurorehabil Neural Repair 2006;20:5-13.
11. Salazar DL, Uchida N, Hamers FP et al. Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. Plos One 2010;5:e12272.
12. Karimi-Abdolrezaee S, Eftekharpour E, Wang J et al. Synergistic effects of transplanted adult neural stem/progenitor cells, chondroitinase, and growth factors promote functional repair and plasticity of the chronically injured spinal cord. J Neurosci 2010;30:1657-1676.
13. Ronaghi M, Erceg S, Moreno-Manzano V et al. (2010) Challenges of stem cell therapy for spinal cord injury: Human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells? Stem Cells 2010;28:93-99.
14. Tetzlaff W, Okon EB, Karimi-Abdolrezaee S et al. A systematic review of cellular transplantation therapies for spinal cord injury. J Neurotrauma 2011;28:1611-1682.
15. Keirstead HS, Nistor G, Bernal G et al. Human embryonic stem cellderived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005;25: 4694-4705.
16. Kumamaru H, Ohkawa Y, Saiwai H et al. Direct isolation and RNAseq reveal environment-dependent properties of engrafted neural stem/progenitor cells. Nat Commun 2012;3:1140.
17. Wang Z, Gerstein M, Snyder M. RNA-Seq: A revolutionary tool for transcriptomics. Nat Rev Genet 2009;10:57-63.
18. Cloonan N, Forrest ARR, Kolle G et al. Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods 2008;5: 613-619.
19. Cloonan N, Grimmond SM. Transcriptome content and dynamics at single-nucleotide resolution. Genome Biol 2008;9:234.
20. Kumamaru H, Saiwai H, Ohkawa Y et al. Age-related differences in cellular and molecular profiles of inflammatory responses after spinal cord injury. J Cell Physiol 2012;227:1335-1346.
21. Pajoohesh-Ganji A, Byrnes KR, Fatemi G et al. A combined scoring method to assess behavioral recovery after mouse spinal cord injury. Neurosci Res 2010;67:117-125.
22. Okada S, Ishii K, Yamane J et al. In vivo imaging of engrafted neural stem cells: its application in evaluating the optimal timing of transplantation for spinal cord injury. Faseb J 2005;19:1839-1841.
23. Trapnell C, Williams BA, Pertea G et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010;28: 511-U174.
24. Mortazavi A, Williams BA, Mccue K et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008;5: 621-628.
25. Hofstetter CP, Holmstrom NAV, Lilja JA et al. Allodynia limits the usefulness of intraspinal neural stem cell grafts; directed differentiation improves outcome. Nat Neurosci 2005;8:346-353.
26. Rhee SY, Wood V, Dolinski K, Draghici S. Use and misuse of the gene ontology annotations. Nat Rev Genet 2008;9:509-515.
27. Karimi-Abdolrezaee S, Eftekharpour E, Wang J et al. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. J Neurosci 2006;26:3377-3389.
28. Pfeifer K, Vroemen M, Caioni M et al. Autologous adult rodent neural progenitor cell transplantation represents a feasible strategy to promote structural repair in the chronically injured spinal cord. Regen Med 2006;1:255-266.
29. Jones LL, Margolis RU, Tuszynski MH. The chondroitin sulfate proteoglycans neurocan, brevican, phosphacan, and versican are differentially regulated following spinal cord injury. Exp Neurol 2003;182: 399-411.
30. Jones LL, Yamaguchi Y, Stallcup WB et al. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. J Neurosci 2002;22:2792-2803.
31. Ikegami T, Nakamura M, Yamane J et al. Chondroitinase ABC combined with neural stem progenitor cell transplantation enhances graft cell migration and outgrowth of growth-associated protein-43-positive fibers after rat spinal cord injury. Eur J Neurosci 2005;22:3036-3046.
32. Tang XF, Davies JE, Davies SJA. Changes in distribution, cell associations, and protein expression levels of NG2, neurocan, phosphacan, brevican, versican V2, and tenascin-C during acute to chronic maturation of spinal cord scar tissue. J Neurosci Res 2003;71:427-444.
33. Buss A, Pech K, Kakulas BA et al. NG2 and phosphacan are present in the astroglial scar after human traumatic spinal cord injury. BMC Neurol 2009;9:32.
34. Houle JD, Tessler A. Repair of chronic spinal cord injury. Exp Neurol 2003;182:247-260.
35. Anderson MF, Aberg MAI, Nilsson M et al. Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Dev Brain Res 2002;134:115-122.
36. Guillemot F, Zimmer C. From cradle to grave: The multiple roles of fibroblast growth factors in neural development. Neuron 2011;71:574-588.
37. Einstein O, Friedman-Levi Y, Grigoriadis N et al. Transplanted neural precursors enhance host brain-derived myelin regeneration. J Neurosci 2009;29:15694-15702.
38. Kumagai G, Okada Y, Yamane J et al. Roles of ES cell-derived gliogenic neural stem/progenitor cells in functional recovery after spinal cord injury. Plos One 2009;4:e7706.
39. Pluchino S, Zanotti L, Rossi B et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005;436:266-271.
40. Lee JP, Jeyakumar M, Gonzalez R et al. Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 2007;13:439-447.
41. Nakashima K, Wiese S, Yanagisawa M et al. Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J Neurosci 1999;19:5429-5434.
42. Bonni A, Sun Y, NadalVicens M, Bhatt A et al. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 1997;278:477-483.
43. Koblar SA, Turnley AM, Classon BJ et al. Neural precursor differentiation into astrocytes requires signaling through the leukemia inhibitory factor receptor. Proc Natl Acad Sci USA 1998;95:3178-3181.
44. Taga T, Fukuda S. Role of IL-6 in the neural stem cell differentiation. Clin Rev Allergy Immunol 2005;28:249-256.
45. Asano H, Aonuma M, Sanosaka T et al. Astrocyte differentiation of neural precursor cells is enhanced by retinoic acid through a change in epigenetic modification. Stem Cells 2009;27:2744-2752.
46. Annenkov A. The insulin-like growth factor (IGF) receptor type 1 (IGF1R) as an essential component of the signalling network regulating neurogenesis. Mol Neurobiol 2009;40:195-215.
47. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009;32:638-647.
48. Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004;5:146-156.
49. Robel S, Berninger B, Gotz M. The stem cell potential of glia: Lessons from reactive gliosis. Nat Rev Neurosci 2011;12:88-104.
50. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-207.
51. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001;24: 1217-1281.
52. Patel JR, Klein RS. Mediators of oligodendrocyte differentiation during remyelination. FEBS Lett 2011;585:3730-3737.
53. Miron VE, Kuhlmann T, Antel JP. Cells of the oligodendroglial lineage, myelination, and remyelination. Biochim Biophys Acta 2011; 1812:184-193.
54. Storkebaum E, Lambrechts D, Dewerchin M et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005;8:85-92.
55. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
56. Cafferty WBJ, Mcgee AW, Strittmatter SM. Axonal growth therapeutics: Regeneration or sprouting or plasticity? Trends Neurosci 2008; 31:215-220.
57. Raineteau O, Schwab ME. Plasticity of motor systems after incomplete spinal cord injury. Nat Rev Neurosci 2001;2:263-273.